021-51111890
购物车（）
sales@molnova.cn
首页-
Products -
Membrane Transporter/Ion Channel -
P-glycoprotein -
Tariquidar methanesulfonate hydrate
Tariquidar methanesulfonate hydrate
CAS No. 625375-83-9
Tariquidar methanesulfonate hydrate ( XR 9576;XR-9576;XR9576 )
产品货号. M15368 CAS No. 625375-83-9
A potent, specific P-gp inhibitor with Kd of 5.1 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tariquidar methanesulfonate hydrate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, specific P-gp inhibitor with Kd of 5.1 nM.
-
产品描述A potent, specific P-gp inhibitor with Kd of 5.1 nM; potentiates the cytotoxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine in a panel of human MDR cell lines at 25-80 nM; exhibits potent i.v. and p.o. activity without apparently enhancing the plasma pharmacokinetics of paclitaxel or the toxicity of coadministered drugs.Breast Cancer Phase 2 Discontinued
-
同义词XR 9576;XR-9576;XR9576
-
通路Membrane Transporter/Ion Channel
-
靶点P-glycoprotein
-
受体P-glycoprotein
-
研究领域Cancer
-
适应症Breast Cancer
化学信息
-
CAS Number625375-83-9
-
分子量892.99
-
分子式C40H52N4O15S2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 296 mg/mL; H2O: < 8.9 mg/mL
-
SMILESCOC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC.CS(=O)(=O)O.CS(=O)(=O)O.O.O.O
-
化学全称3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-, methanesulfonate, hydrate (1:2:3)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Martin C, et al. Br J Pharmacol. 1999 Sep;128(2):403-11.
2. Mistry P, et al. Cancer Res. 2001 Jan 15;61(2):749-58.
3. Walker J, et al. Eur J Cancer. 2004 Mar;40(4):594-605.
2. Mistry P, et al. Cancer Res. 2001 Jan 15;61(2):749-58.
3. Walker J, et al. Eur J Cancer. 2004 Mar;40(4):594-605.
产品手册
关联产品
-
Dofequidar fumarate
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.
-
Laniquidar
An orally active, third-generation P-glycoprotein inhibitor that inhibits the drug efflux pump P-glycoprotein.
-
Elacridar hydrochlor...
A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
